The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 18, 2008
Filed:
Dec. 18, 2002
Juan Lorenzo Catena Ruiz, L'Hospitalet de Llobregat, ES;
Carles Farrerons Gallemi, Mataro, ES;
Anna Fernandez Serrat, Sant Cugat del Vallès, ES;
Ignacio José Miquel Bono, L'Hospitalet de Llobregat, ES;
Dolors Balsa Lopez, Badalona, ES;
Carmen Lagunas Arnal, L'Hospitalet de Llobregat, ES;
Carolina Salcedo Roca, Corbera, ES;
Natividad Toledo Mesa, Vilanova del Vallès, ES;
Andrés Fernandez Garcia, Barcelona, ES;
Juan Lorenzo Catena Ruiz, L'Hospitalet de Llobregat, ES;
Carles Farrerons Gallemi, Mataro, ES;
Anna Fernandez Serrat, Sant Cugat del Vallès, ES;
Ignacio José Miquel Bono, L'Hospitalet de Llobregat, ES;
Dolors Balsa Lopez, Badalona, ES;
Carmen Lagunas Arnal, L'Hospitalet de Llobregat, ES;
Carolina Salcedo Roca, Corbera, ES;
Natividad Toledo Mesa, Vilanova del Vallès, ES;
Andrés Fernandez Garcia, Barcelona, ES;
Chiesi Farmaceutici S.p.A., Parma, IT;
Abstract
Carbamate of general formula (I), wherein R1, R2, and R3 are H, OH, NO, SH, CN, F, Cl, Br, I, COOH, CONH, (C-C)-alkoxycarbonyl, (C-C)-alkylsulfanyl, (C-C)-alkylsulfinyl, (C-C)-alkylsulfonyl, (C-C)-alkoxyl optionally substituted with one or several F, and (C-C)-alkyl optionally substituted with one or several F or OH; R4 is cycloalkyl, phenyl, heteroaryl or a bicyclic ring system; R5 is cycloalkyl, (C-C)-alkyl, a substituted (C-C)-alkyl; and Xis a physiologically acceptable anion. Carbamate (I) is selective Mreceptor antagonists versus Mreceptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particularly, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions.